This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pagliaro, L. C. Articles by Dinney, C. P. Search for Related Content PubMed PubMed Citation Articles by Pagliaro, L. C. Articles by Dinney, C. P. Related Articles Related Correspondence Related Reply Social Bookmarking                            What's this?

Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy

Lance C. Pagliaro, Afsaneh Keyhani, Dallas Williams, Denise Woods, Baoshun Liu, Paul Perrotte, Joel W. Slaton, James A. Merritt, H. Barton Grossman, Colin P. Dinney

From the Department of Genitourinary Medical Oncology and the Department of Urology, The University of Texas M. D. Anderson Cancer Center; and Introgen Therapeutics, Inc, Houston, TX.

Address reprint requests to Lance C. Pagliaro, MD, Department of Genitourinary Medical Oncology, Box 427, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009; email: lpagliar{at}mdanderson.org.

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer.

Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (10¹⁰ particles to 10¹² particles) or on either 4 or 8 consecutive days at a single dose level (10¹² particles).

Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21^waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response.

Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

Supported, in part, by grant nos. CA76233 and CA91846, and in part by core grant no. CA16672 from the National Cancer Institute, Bethesda, MD.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Doomed Trials for Promising Adenoviruses: A Rationale for Success
  Enrique Casado, Javier De Castro, Cristóbal Belda-Iniesta, Jaime Feliu, Manuel González-Barón, and Waleed Arafat
  JCO 2004 22: 1162-1163 [Full Text]

Related Reply

• In Reply:
  Lance C. Pagliaro
  JCO 2004 22: 1163-1164 [Full Text]

This article has been cited by other articles:

				A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]

				T. Fujiwara, N. Tanaka, S. Kanazawa, S. Ohtani, Y. Saijo, T. Nukiwa, K. Yoshimura, T. Sato, Y. Eto, S. Chada, et al. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1689 - 1699. [Abstract] [Full Text] [PDF]

				N. Ramesh, Y. Ge, D. L. Ennist, M. Zhu, M. Mina, S. Ganesh, P. S. Reddy, and D.-C. Yu CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor-Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer Clin. Cancer Res., January 1, 2006; 12(1): 305 - 313. [Abstract] [Full Text] [PDF]

				E. Casado, J. De Castro, C. Belda-Iniesta, J. Feliu, M. Gonzalez-Baron, and W. Arafat Doomed Trials for Promising Adenoviruses: A Rationale for Success J. Clin. Oncol., March 15, 2004; 22(6): 1162 - 1163. [Full Text] [PDF]

				L. C. Pagliaro In Reply: J. Clin. Oncol., March 15, 2004; 22(6): 1163 - 1164. [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				S. J. Russell and K.-W. Peng Primer on Medical Genomics Part X: Gene Therapy Mayo Clin. Proc., November 1, 2003; 78(11): 1370 - 1383. [Abstract] [PDF]

				P. P. Connell and R. R. Weichselbaum Gene Therapy: The Challenges of Translating Laboratory Research Into Clinical Practice J. Clin. Oncol., June 15, 2003; 21(12): 2230 - 2231. [Full Text] [PDF]